1-Bromo-5-fluoro-4-iodo-2-methylbenzene | 677777-56-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Bromo-5-fluoro-4-iodo-2-methylbenzene
• CAS: 677777-56-9
• 化学式: C₇H₅BrFI
• 分子量: 314.92
• InChiKey: ISLHUHGOROORJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-Bromo-5-fluoro-4-iodo-2-methylbenzene 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium acetate 、 palladium diacetate 、 tricyclohexylphosphine tetrafluoroborate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 生成 2-[4-(dimethylphosphoryl)-5-fluoro-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
  参考文献：
  名称：

  MODULATORS OF TNF-α ACTIVITY

  摘要：

  Provided herein are inhibitors of TNFα, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the TNFα inhibitory compounds for the treatment of diseases or disorders.

  公开号：

  WO2024112796A1

文献信息

• FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG
  申请人：Sato Tsutomu

  公开号：US20100234609A1

  公开（公告）日：2010-09-16

  Provided are a compound represented by Formula (I): wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from a hydrogen atom, a C 1-6 alkyl group which may be substituted, a C 7-14 aralkyl group which may be substituted and —C(═O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f). or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  提供的是一个由式(I)表示的化合物：其中R1、R2、R3和R4分别独立地选择自氢原子、可能被取代的C1-6烷基、可能被取代的C7-14芳基烷基和—C(═O)Rx；n表示选择自1和2的整数；环Ar选择自以下式(a)到(f)所表示的基团。或其前药或其药学上可接受的盐，以及含有此化合物或其前药或其药学上可接受的盐的药物剂和药物组合物。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：Buckman Brad O.

  公开号：US20130072449A1

  公开（公告）日：2013-03-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
• US8207134B2
  申请人：——

  公开号：US8207134B2

  公开（公告）日：2012-06-26
• US8975235B2
  申请人：——

  公开号：US8975235B2

  公开（公告）日：2015-03-10